The findings, published in Genome Medicine, challenge the conventional picture of a tumour as a mass of rapidly multiplying cells. Within the same tumour, researchers identified regions dominated by proliferating cancer cells alongside distinct pockets populated by quiescent cells. These dormant cells have temporarily paused their cell cycle, a biological state that makes them far less vulnerable to many chemotherapy drugs, which are designed to damage cells as they divide. Although they may be inactive, the cells can later re-enter the cell cycle and contribute to tumour growth, recurrence or metastatic spread.

“Quiescent cancer cells are very dangerous,” said Dr Alexis Barr, co-lead author and head of the Cell Cycle Control group at the MRC Laboratory of Medical Sciences. Cancer cells can enter quiescence when they encounter stresses such as limited nutrients, oxygen shortages or inadequate blood supply. Rather than dying, they reduce their activity and wait for conditions to improve. This survival strategy resembles hibernation: the cells conserve resources during hostile conditions and may reactivate after treatment has ended, when the tumour environment becomes more favourable.

To locate and characterise these cells, Barr’s team collaborated with Dr Maria Secrier’s computational biology group at UCL. The researchers integrated single-cell RNA sequencing with spatial transcriptomics, two technologies that provide complementary views of tumour biology. Single-cell RNA sequencing measures the genes active in individual cells, allowing researchers to distinguish proliferating, dormant, immune and connective-tissue populations. Spatial transcriptomics adds the missing geography by recording where those cells are located within the tumour and which other cell types occupy the surrounding tissue.

This combined approach produced a cellular map showing that features associated with treatment resistance can exist before therapy begins. The researchers detected tumour cells resembling therapy-resistant populations in untreated breast cancers, suggesting that resistance is not always created by exposure to drugs. Some resistant characteristics may already be embedded within the tumour’s cellular organisation. The pattern appeared in both aggressive breast cancer subtypes and slower-developing forms, an important observation because dormancy has often been linked primarily with less aggressive disease.

The most striking discovery was the repeated association between dormant cancer cells and two types of neighbouring cells: CXCL10-positive macrophages and myofibroblastic cancer-associated fibroblasts. Macrophages are immune cells that can perform very different functions depending on signals from their surroundings. Cancer-associated fibroblasts are connective-tissue cells reprogrammed by tumours to support tumour architecture, blood-vessel formation and disease progression. In the mapped tumours, these populations gathered around dormant cancer cells, creating what the researchers described as a potential protective shell.

The biological meaning of this arrangement remains unresolved. The surrounding macrophages and fibroblasts may actively encourage cancer cells to enter or remain in quiescence, or dormant cancer cells may recruit and reshape nearby support cells. The relationship could also operate in both directions, with tumour cells and their environment continually influencing one another. The researchers caution that the spatial association does not yet prove that these cells form a physical barrier against chemotherapy or immune cells. Experimental studies will be needed to determine whether the proposed “shield” directly protects dormant cancer cells and which molecular signals maintain the niche.

The tumour maps also revealed increased activity of the complement pathway in dormant regions. Complement is a network of immune proteins that can recognise and mark abnormal cells, regulate inflammation and influence interactions between immune and tumour cells. Its heightened activity in quiescent niches could provide a vulnerability, although the outcome may depend on the precise complement signals present and how cancer cells manipulate them. Treatments aimed at this pathway, or at the macrophages and fibroblasts surrounding dormant cells, could eventually be combined with therapies that attack actively dividing tumour cells.

The study therefore points towards a treatment strategy that targets the tumour as an ecosystem rather than as a single, uniform population. Drugs that eliminate proliferating cancer cells may leave dormant cells untouched, while therapies directed at dormant niches could disrupt the support system that enables them to survive. Combining these approaches might suppress tumour growth in the short term while reducing the reservoir of cells capable of causing relapse years later. However, the researchers emphasise that their predictions are based on computational analysis of publicly available tumour data and must be tested in laboratory models and clinical studies before they can guide treatment.

By placing dormant cancer cells on the map, the work offers a more detailed explanation of why breast cancer can return after apparently successful therapy. The danger may not lie only in a small number of unusually resilient cancer cells, but in the specialised neighbourhoods that help them persist. Understanding how cancer cells, immune cells and fibroblasts co-evolve inside these regions could enable more precise drug combinations—treating active tumour growth while dismantling the biological shelters that allow hidden disease to survive.

Subject of Research: Spatial organisation of proliferating and dormant breast cancer cells, their interactions with immune and stromal cells, and potential treatment-resistant tumour niches.

Article Title: Spatial ecology of breast cancer reveals co-evolution of proliferative and dormant niches

Web References: https://link.springer.com/article/10.1186/s13073-026-01711-0

References: Genome Medicine; DOI: 10.1186/s13073-026-01711-0

Keywords: Breast cancer, dormant cancer cells, quiescence, tumour microenvironment, spatial transcriptomics, single-cell RNA sequencing, macrophages, cancer-associated fibroblasts, complement pathway, treatment resistance, cancer recurrence, tumour niches

The phenomenon of tumor dormancy, where cancer cells enter a quiescent state, has long puzzled researchers. Cancer cells are known to exhibit remarkable plasticity, allowing them to adapt to hostile environments, evade immune surveillance, and enter into a seemingly inactive state. This dormant phase can last for extended periods, creating a deceptive sense of security for patients who believe they have overcome the disease. However, the dormant cells harbor the potential for resurgence, a process that poses significant risks for patients in remission.

In their research, Tufail and colleagues explore several mechanisms that govern the state of dormancy in tumors. One of the important factors is the cellular microenvironment, which significantly influences tumor behavior. Tumor-associated fibroblasts, immune cells, and extracellular matrix components create a complex milieu that can either support dormancy or trigger reactivation. Understanding the interactions within this microenvironment is crucial for developing interventions aimed at preventing recurrence.

Cellular signaling pathways also play a pivotal role in the dormancy and relapse of cancer cells. Key pathways, such as the PI3K/Akt and TGF-β signaling, have been implicated in the maintenance of cellular quiescence. When these pathways become dysregulated, dormant cancer cells can reactivate, leading to proliferation and invasive growth. The research highlights the importance of identifying biomarkers associated with these pathways, as they could serve as targets for therapeutic intervention.

Another interesting aspect of their study is the recognition of genetic and epigenetic alterations within dormant tumor cells. These alterations can contribute to the genomic plasticity of cancer cells, enabling them to survive unfavorable conditions or respond to therapeutic pressures. Tufail et al. emphasize the significance of studying these modifications, as they may hold clues regarding the prevention of cancer recurrence and the development of next-generation therapies.

Immune evasion is also central to the survival of dormant tumors. The ability of cancer cells to escape immune detection is a cornerstone of their persistence. The research provides insights into how dormant cells can exploit immune checkpoints and other immunosuppressive mechanisms to remain hidden. This revelation opens up avenues for novel immunotherapeutic approaches that aim to reactivate the immune response against these elusive cells, ideally before they transition back to an active proliferative state.

Moreover, the study dives into the role of metabolic reprogramming in maintaining cancer dormancy. Dormant tumor cells often exhibit altered metabolic pathways that enable them to survive in a state of low energy demand. By examining these metabolic adaptations, researchers can potentially discover vulnerabilities within dormant cancers that can be exploited therapeutically, shifting the paradigm towards more effective strategies for long-term control of the disease.

Tufail, Jiang, and Li also underline the therapeutic implications of their findings. As oncologists increasingly face the challenge of cancer recurrence, the understanding of dormant tumor biology becomes essential. Therapies that promote the clearance of dormant cells or that re-sensitize them to therapy could markedly improve patient outcomes. With advancements in our understanding of dormancy, the future of anticancer strategies may involve not only killing actively dividing cells but also effectively targeting the hidden reservoirs of dormant units.

In addition to biochemical mechanisms, psychological factors also contribute to the perception and management of cancer dormancy. Patients often experience anxiety regarding the possibility of relapse, which can affect their overall quality of life. The study addresses the need for comprehensive care that supports patients emotionally and psychologically, to help them navigate the complexities of living with the knowledge of potential recurrence.

Moreover, educational initiatives to raise awareness about the implications of tumor dormancy among patients and healthcare providers are essential. Enhanced understanding of this phenomenon can lead to better monitoring strategies post-treatment and ensure timely interventions when signs of relapse occur. Empowering patients with knowledge regarding their cancer journey increases engagement and compliance with follow-up care, resulting in improved long-term management of their health.

The ongoing efforts to unravel the complexities surrounding tumor dormancy necessitate multi-disciplinary collaboration among oncologists, immunologists, and molecular biologists. Such cooperation will foster progress towards the development of integrated treatment approaches that address both active and dormant phases of cancer. Researchers like Tufail and their peers represent a new wave of scientists pursuing innovative solutions to age-old challenges in oncology.

As we look to the future, it is clear that cancer research continues to evolve. The findings regarding tumor dormancy and relapse raise critical questions that warrant further exploration. With continued investment in this field, we may soon be equipped with the tools necessary to both detect and combat the silent threat posed by dormant tumor cells. Achieving breakthroughs will not only improve survival rates but may also transform the landscape of cancer therapies, providing hope to millions affected by this relentless disease.

In conclusion, as Tufail and colleagues articulate in their research, the complex relationship between tumor dormancy and cancer relapse is an area ripe for exploration. By dissecting the molecular underpinnings that guide this intricate dance, we may one day pave the way for innovative therapies that effectively keep cancer at bay—permanently. The knowledge gained from these studies holds the potential to resonate throughout the oncology community, shaping how we approach existing cancers and preventing future occurrences with vigilance and strategic foresight.

Subject of Research: Tumor dormancy and mechanisms of cancer recurrence

Article Title: Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Article References:

Tufail, M., Jiang, CH. & Li, N. Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence. Military Med Res 12, 7 (2025). https://doi.org/10.1186/s40779-025-00595-2

Image Credits: AI Generated

DOI: 10.1186/s40779-025-00595-2

Keywords: Tumor dormancy, cancer recurrence, molecular mechanisms, immune evasion, metabolic reprogramming, therapeutic targets, patient care.